Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02866240 · ClinicalTrials.gov registry record · NA
Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy
A NA study, sponsored by Neuroelectrics Corporation.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02866240 is a NA study that has completed, run by Neuroelectrics Corporation. The registered enrollment target is 20 participants.
The verdict
NCT02866240, a NA study, has completed, sponsored by Neuroelectrics Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral cortical surface of any lobe. All patients and referring physicians will be requested to maintain their current antiepileptic drugs throughout the study with changes after enrollment permitted only to maintain pre-enrollment drug levels, or if clinically necessary. The primary outcome measure will be the change in seizure frequency (seizures/week) as compared to baseline. Patients with medically-refractory neocortical epilepsy will receive cathodal tDCS administered to the seizure focus for 10 sessions over a 2-week period with the allowance of make-up sessions in week three. Subjects will be evaluated at baseline, during the stimulation sessions, and 8 weeks after the completion of the tDCS visits
Interventions
- DEVICE Cathodal Transcranial Direct Current Stimulation (tDCS).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02866240
The ClinicalTrials.gov registry entry for NCT02866240 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuroelectrics Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cathodal Transcranial Direct Current Stimulation (tDCS). is the first listed.
NCT02866240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02866240 about?
NCT02866240 is a clinical study titled "Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy". This is a single site, non-randomized, prospective, open-label, interventional pilot/feasibility study. Patients recruited will have medically-refractory focal neocortical epilepsy, defined on the basis of presence of focal spikes and (if available) focal seizure onsets originating from the lateral ...
What is the current status of trial NCT02866240?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-09-21. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT02866240?
The interventions under investigation include: Cathodal Transcranial Direct Current Stimulation (tDCS). (DEVICE).
Who is sponsoring clinical trial NCT02866240?
This trial is sponsored by Neuroelectrics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.